A new study reports a novel drug designed to treat migraine was associated with fewer headache hours for sufferers within 3 to 7 days following their first injection.
A new study offers insight into the neurological processes involved in fear and anxiety.
According to researchers, a single large dose if psilocybin, the active hallucinogenic compound found in magic mushrooms, helped provide relief for people suffering from cancer related depression and anxiety for up to six months.
Researchers report Yohimbine, a dietary supplement derived from tree bark, shows potential in the treatment of sleep apnea, especially for those with anxiety disorders and high blood pressure.
Glioblastmoa brain cancer patients who received an experimental vaccines in combination with chemotherapy showed improved suitability and tolerated the treatment well, a new study reports.
A new drug has been cleared for human trials in patients with anaplastic astrocytoma and glioblastoma brain cancers. The drug, PAC-1, is reported to spur cancer cells to self destruct and has proven to be effective in animal models of brain cancers.
According to researchers, Botulinum toxin, or Botox, injections can help to reduce the frequency of chronic migraines. Compared to those treated with a placebo, migraine suffers experienced 1.6 fewer attacks per month following Botox injections.
Researchers report popular benzodiazepine sleep medications, such as Ambien and Halcion, caused test subjects to sleep through fire alarm drills. However, a newly developed class of sleeping medications perverse the ability to wake in response to threat.
EIDD-2801, a new antiviral drug, has the potential to treat coronavirus. A new study reveals the drug can prevent severe lung injury in mouse models and cultured human lung cells infected with COVID-19. The drug will soon be ready for human testing.